Streetbeat News

Regulatory

RLMD

Relmada Therapeutics, Inc. (NASDAQ:RLMD) announced new preclinical data on its novel psilocybin, showing significant reductions in liver fat content, plasma glucose levels, and body weight gain in a mice model. The company plans to initiate a single-ascending dose Phase 1 trial in patients in early 2024. The data will be presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2023.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 12:41 pm

GOOG

GOOGL

Google, a subsidiary of Alphabet Inc, and Discord Inc have been hosting a chat for users of Bard, Google's AI-powered chatbot. There are concerns about the reliability of large language models (LLMs) like Bard, and the need for independent verification of their outputs. Users have raised concerns about Bard generating inaccurate information and potentially hazardous advice. Google has introduced a search button on Bard to allow users to validate the AI-generated responses. The success of Bard is crucial for Google as generative AI technologies threaten Google's dominance in the search market.

Portfolio Pulse from Anusuya Lahiri

October 11, 2023 | 12:40 pm

EIS

SPY

USO

VGK

Russian President Putin has stated that the conflict in Israel could affect logistics but not oil output. He also mentioned that the U.S. is increasing tensions in the region by deploying its navy.

Portfolio Pulse from Charles Gross

October 11, 2023 | 12:39 pm

HYLN

Hyliion Holdings Corp (HYLN) shares have dropped by 35.9% following the company's announcement that it is exploring strategic options for its powertrain business due to slow market adoption and regulatory compliance needs. The company will continue commercializing the KARNO generator but will pause efforts like securing orders for their Hypertruck ERX and new powertrain development work. A conference call to discuss this strategic review will be held on October 11.

Portfolio Pulse from Henry Khederian

October 11, 2023 | 12:39 pm

SILO

Silo Pharma has initiated a human factor study of SPC-15, a drug intended for the treatment of Post-Traumatic Stress Disorder (PTSD).

Portfolio Pulse from Bill Haddad

October 11, 2023 | 12:37 pm

SPY

The USA Core Producer Price Index (PPI) for September increased by 0.3%, higher than the estimated 0.2% and the prior 0.2%.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 12:32 pm

SPY

The Producer Price Index (PPI) for September has come in at 2.2%, higher than the estimated 1.6%.

Portfolio Pulse from Bill Haddad

October 11, 2023 | 12:31 pm

SPY

The USA Core Producer Price Index (PPI) for September was reported at 2.7%, higher than the estimated 2.3% and the prior value of 2.2%.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 12:30 pm

BSX

Boston Scientific has received FDA approval for its Spinal Cord Stimulation therapy for people living with Diabetic Peripheral Neuropathy. This approval could potentially open up a new market for the company's products.

Portfolio Pulse from Bill Haddad

October 11, 2023 | 12:25 pm

SPY

UNG

USO

VGK

Russian President Vladimir Putin has stated that Russia will continue to significantly contribute to the balancing of the global energy market, according to Reuters.

Portfolio Pulse from Charles Gross

October 11, 2023 | 12:12 pm